ClinicalTrials.gg
CompletedNCT04480827Updated Aug 14, 2024Results posted

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

A Phase 1 interventional study of Aramchol free acid tablet 600mg, single dose and Aramchol free acid tablet 300mg, bid in Hepatic Impairment, sponsored by Galmed Research and Development, Ltd.. Completed at 3 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-14.

Sponsored by Galmed Research and Development, Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2020, registered Jun 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

Phase 1, multicenter, open-label, 2-part, single- and multiple-dose study designed to assess the effect of hepatic insufficiency on the PK of aramchol

Read the detailed description

Each of the 2 parts of the study consisted of a screening period, a check in day, a treatment period, and an end of study (EOS) visit.

In Part 1 (single-dose): 39 subjects were enrolled: 8 subjects each in the mild (Cohort A), moderate (Cohort B), and severe (Cohort C) hepatic impairment cohorts and 15 healthy control subjects with normal hepatic function (Cohort D). Enrollment of 8 subjects with mild hepatic impairment (Cohort A) proceeded only if there is evidence of reduced clearance of aramchol in Cohort B. Assignment to cohorts A to C, was according to Child Pugh classification system.

Serial blood samples for PK analysis of aramchol concentrations in plasma were collected before dosing (0 hour) and up to 168 hours for healthy subjects and 240 hours for hepatically impaired subjects after administration of aramchol.

In Part 2 (multiple-dose), a cohort of 4 subjects comprising of mild, 7 moderate , as well as a cohort of 7 healthy volunteers was administered with aramchol as multiple doses to obtain the PK profile of aramchol at steady state. Aramchol was given twice daily for 12 days. Trough blood samples for analysis of aramchol plasma concentrations was collected before the AM dose on several days and at intervals to 12 hours after the AM dose on Day 12.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • Pharmacokinetics
03

In context

Lead sponsor

Galmed Research and Development, Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is male or female 18 to 79 years of age, inclusive.
  2. The subject has a of 19 to 40 kg/m2, inclusive, at screening.
  3. Females of must practice a highly effective method of throughout the study period and for 1 month after treatment discontinuation.
  4. Male subjects with female partners of childbearing potential must be vasectomized, be willing to use an acceptable method of birth control, or practice abstinence during the study.
  5. The subject has a resting pulse rate of ≥40 and \<100 beats per minute with no deviation as judged by the investigator.
  6. The subject has a corrected for heart rate using Fridericia's formula of \<500 msec.
  7. The subject agrees to comply with all protocol requirements.
  8. The subject is able to provide written .

    Additional Inclusion Criteria for Healthy Subjects Only (Cohort D):

  9. The subject has normal hepatic function.
  10. The subject has a resting blood pressure of 90 to 150 mm Hg (systolic) and 50 to 100 mm Hg (diastolic).
  11. The subject is judged by the investigator to be in good general health, as determined by medical history, clinical laboratory assessments, vital sign measurements, 12 lead (ECG) results, and physical examination findings.

    Additional Inclusion Criteria for Subjects With Hepatic Impairment Only (Cohorts A, B, and C):

  12. The subject has cirrhosis with evidence of impaired liver function. The etiology of the cirrhosis may be alcoholic, , nonalcoholic steatohepatitis, or chronic viral hepatitis type B or C.
  13. The subject has chronic (more than 6 months) and stable hepatic impairment (ie, no acute episodes of illness within 30 days before screening due to deterioration of hepatic function) as assessed by a classification score of mild (5 to 6 points), moderate (7 to 9 points), or severe (10 to 15 points).
  14. The subject has a resting blood pressure of 90 to 155 mm Hg (systolic) and 50 to 100 mm Hg (diastolic).
  15. The subject is judged by the investigator to be in good general health, as determined by medical history, clinical laboratory assessments, vital sign measurements, 12 lead ECG results, and physical examination findings, except for findings that, as judged by the investigator, are consistent with the subject's hepatic impairment or other stable concomitant medical conditions.

Exclusion criteria

Exclusion Criteria:

  1. The subject has a history or clinical manifestations of a significant neurological, renal, cardiovascular, gastrointestinal, pulmonary, hematologic, immunologic, or psychiatric disease that would preclude study participation, as judged by the investigator.
  2. The subject has a positive test result for type 1 or 2 antibodies at screening.
  3. The subject has a history of drug abuse within 3 months before screening.
  4. The subject has a history of alcoholism within 3 months before screening, or excessive alcohol consumption (regular alcohol intake >15 units per week) (1 unit is equal to approximately ½ pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure [25 mL] of spirits).
  5. The subject smokes >10 cigarettes daily and is unwilling to reduce to \<5 daily from the time of screening through the last PK sample.
  6. The subject is unable or unwilling to abstain from alcohol, caffeine, xanthine containing beverages or food (eg, coffee, tea, chocolate, and caffeinated sodas, colas), grapefruit, grapefruit juice, Seville oranges, or products containing any of these, from 48 hours prior to study drug dosing until discharge.
  7. The subject is involved in strenuous activity or contact sports within 24 hours of the first dose of study drug or during the study.
  8. The subject has donated blood or blood products >450 mL within 3 months before the first dose of study drug.
  9. The subject has a presence or history of relevant drug and/or food allergies (ie, allergy to aramchol, cholic acid, or any , or any significant food allergy.
  10. The subject has received study drug in another study within 30 days of dosing.
  11. In the opinion of the investigator, the subject is not suitable for entry into the study.

For additional exclusion criteria specific to hepatic impaired subjects and healthy volunteers, see protocol.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Part 1: Mild Hepatic Impairment (Cohort A)

    8 mild hepatic impaired subjects

    Drug: Aramchol free acid tablet 600mg, single dose

  • Experimental
    Part 1: Moderate Hepatic Impairment (Cohort B)

    8 moderate hepatic impaired subjects

    Drug: Aramchol free acid tablet 600mg, single dose

  • Experimental
    Part 1: Severe Hepatic Impairment (Cohort C)

    8 severe hepatic impaired subjects

    Drug: Aramchol free acid tablet 600mg, single dose

  • Experimental
    Part 1: Healthy Volunteers (Cohort D)

    15 matched healthy volunteers

    Drug: Aramchol free acid tablet 600mg, single dose

  • Experimental
    Part 2: Mild Hepatic Impairment Cohort

    4 mild hepatic impaired subjects

    Drug: Aramchol free acid tablet 300mg, bid

  • Experimental
    Part 2: Moderate Hepatic Impairment Cohort

    7 moderate hepatic impaired subjects

    Drug: Aramchol free acid tablet 300mg, bid

  • Experimental
    Part 2: Healthy Volunteers Cohort

    7 matched healthy volunteers

    Drug: Aramchol free acid tablet 300mg, bid

Interventions

  • DrugAramchol free acid tablet 600mg, single dose

    Aramchol free acid tablet 600mg, single dose

    Also known as: Cholan-24-oic acid 7,12-dihydroxy3-[(1- oxoeicosyl)amino]-(3β,5β,7α,12α) salt with N-methyl-(D)-glucamine

  • DrugAramchol free acid tablet 300mg, bid

    Aramchol acid tablet 300mg, bid for 12 days

    Also known as: Cholan-24-oic acid 7,12-dihydroxy3-[(1- oxoeicosyl)amino]-(3β,5β,7α,12α) salt with N-methyl-(D)-glucamine

06

What researchers measure

Primary outcomes

  1. AUC0-tau, Steady State

    AUC from time 0 to the dosing interval tau measured at steady state. Blood was collected at the following time points: before dosing (0 hour) and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 48, 72, 96, 120, 144, 168, 192, and 240 hours

    Time frame: Day 12

  2. Cmax,ss

    Maximum plasma concentrations (Cmax,ss) Blood was collected at the following time points: before dosing (0 hour) and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 48, 72, 96, 120, 144, 168, 192, and 240 hours

    Time frame: Day 12

  3. Apparent Total Oral Clearance, Single Dose

    CL/F measured after single dose in Part 1 Blood was collected at the following time points: before dosing (0 hour) and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 48, 72, 96, 120, 144, 168, 192, and 240 hours

    Time frame: Day 11

Secondary outcomes

  1. Number of Subjects With Significant TEAEs

    The number of significant treatment-related adverse events

    Time frame: Part 1: up to 22 days; Part 2: up to 27 days

07

Results

Posted Aug 14, 2024

Participant flow

Participant flow — Overall Study
MilestonePart 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2- Moderate Hepatic Impairment CohortPart 2: Healthy Volunteers Cohort
Started88815477
Completed88815467
Not completed0000010
Withdrew: Adverse event0000010

Outcome measures

PrimaryAUC0-tau, Steady State

AUC from time 0 to the dosing interval tau measured at steady state. Blood was collected at the following time points: before dosing (0 hour) and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 48, 72, 96, 120, 144, 168, 192, and 240 hours

Time frame:
Day 12
Reported as:
Geometric mean · h•ng/mL
AUC0-tau, Steady State
h•ng/mLPart 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2: Moderate Impairment CohortPart 2: Healthy Volunteers Cohort
AUC0-tau, Steady State96100 ± 138.29107000 ± 154.13103000 ± 148.0969500 ± 063300 ± 4.355900 ± 31.461400 ± 26
PrimaryCmax,ss

Maximum plasma concentrations (Cmax,ss) Blood was collected at the following time points: before dosing (0 hour) and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 48, 72, 96, 120, 144, 168, 192, and 240 hours

Time frame:
Day 12
Reported as:
Geometric mean · ng/mL
Cmax,ss
ng/mLPart 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2: Moderate Hepatic Impairment CohortPart 2: Healthy Volunteers Cohort
Cmax,ss1950 ± 138.171890 ± 134.261480 ± 105.221410 ± 05750 ± 5.25380 ± 26.16040 ± 21.3
PrimaryApparent Total Oral Clearance, Single Dose

CL/F measured after single dose in Part 1 Blood was collected at the following time points: before dosing (0 hour) and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 18, 24, 48, 72, 96, 120, 144, 168, 192, and 240 hours

Time frame:
Day 11
Reported as:
Geometric mean · L/h
Apparent Total Oral Clearance, Single Dose
L/hPart 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2: Moderate Impairment CohortPart 2: Healthy Volunteers Cohort
Apparent Total Oral Clearance, Single Dose5.96 ± 43.85.23 ± 29.25.86 ± 52.58.01 ± 50.1———
SecondaryNumber of Subjects With Significant TEAEs

The number of significant treatment-related adverse events

Time frame:
Part 1: up to 22 days; Part 2: up to 27 days
Reported as:
Count of participants · Participants
Number of Subjects With Significant TEAEs
ParticipantsPart 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2: Moderate Hepatic Impairment CohortPart 2: Healthy Volunteers Cohort
Number of Subjects With Significant TEAEs0000000

Adverse events

Collected over Adverse events were assessed from the time the subject signed the informed consent until study completion (i.e., End of study- 30 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Mild Hepatic Impairment (Cohort A)0/8 (0%)0/8 (0%)0/8 (0%)
Part 1: Moderate Hepatic Impairment (Cohort B)0/8 (0%)0/8 (0%)0/8 (0%)
Part 1: Severe Hepatic Impairment (Cohort C)0/8 (0%)0/8 (0%)0/8 (0%)
Part 1: Healthy Volunteers (Cohort D)0/15 (0%)0/15 (0%)0/15 (0%)
Part 2: Mild Hepatic Impairment Cohort0/4 (0%)0/4 (0%)0/4 (0%)
Part 2: Moderate Impairment Cohort0/7 (0%)0/7 (0%)1/7 (14.3%)
Part 2: Healthy Volunteers Cohort0/7 (0%)0/7 (0%)0/7 (0%)
Most frequent other events
Most frequent other events
EventPart 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2: Moderate Impairment CohortPart 2: Healthy Volunteers Cohort
ThrombocytopeniaBlood and lymphatic system disorders0/80/80/80/150/41/70/7

Baseline characteristics

Population in Part 1 included mild hepatic impairment subjects, moderate hepatic impairment subjects, severe hepatic subjects, and healthy matched control subjects. Population in Part 2 included mild hepatic impairment subjects, moderate hepatic impairment subjects, and healthy matched control subjects.

Age, Categorical
Age, Categorical(Participants)Part 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2: Moderate Hepatic Impairment CohortPart 2: Healthy Volunteers CohortTotal
<=18 years00000000
Between 18 and 65 years7551024639
>=65 years133523118
Age, Continuous
Age, Continuous(Years)Part 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2: Moderate Hepatic Impairment CohortPart 2: Healthy Volunteers CohortTotal
Mean59.1 ± 8.1063.3 ± 9.0262.0 ± 6.3559.7 ± 8.5064.0 ± 4.1660.1 ± 8.4760.1 ± 6.8260.86 ± 7.63
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2: Moderate Hepatic Impairment CohortPart 2: Healthy Volunteers CohortTotal
Female134411216
Male7541136541
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2: Moderate Hepatic Impairment CohortPart 2: Healthy Volunteers CohortTotal
Hispanic or Latino041113313
Not Hispanic or Latino8471434444
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2: Moderate Hepatic Impairment CohortPart 2: Healthy Volunteers CohortTotal
American Indian or Alaska Native00010001
Asian10001002
Native Hawaiian or Other Pacific Islander00000000
Black or African American20031017
White5881027646
More than one race00010001
Unknown or Not Reported00000000
Region of Enrollment
Region of Enrollment(Participants)Part 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2: Moderate Hepatic Impairment CohortPart 2: Healthy Volunteers CohortTotal
United States8881547757
Child-Pugh total scores
Child-Pugh total scores(points)Part 1: Mild Hepatic Impairment (Cohort A)Part 1: Moderate Hepatic Impairment (Cohort B)Part 1: Severe Hepatic Impairment (Cohort C)Part 1: Healthy Volunteers (Cohort D)Part 2: Mild Hepatic Impairment CohortPart 2: Moderate Hepatic Impairment CohortPart 2: Healthy Volunteers CohortTotal
Mean5.38 ± 0.5188.25 ± 0.88611.50 ± 1.512—5.75 ± 0.57.71 ± 0.756—7.94 ± 2.25
08

Study locations

3 sites
  • Division of Clinical Pharmacology, University of Miami
    Miami, Florida 33136, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Alliance for Multispecialty Research
    Knoxville, Tennessee 37920, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Mar 2022, 25 months.

Results were first posted in Aug 2024, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2020
First posted
Jul 21, 2020
StartActual
Feb 13, 2020
Primary completionActual
Mar 24, 2022
CompletionActual
Mar 24, 2022
Results first posted
Aug 14, 2024
Last update
Aug 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04480827
Lead sponsor
Galmed Research and Development, Ltd.
Responsible party
Sponsor
First posted
Jul 21, 2020
Start date
Feb 13, 2020
Primary completion
Mar 24, 2022
Completion
Mar 24, 2022
Results posted
Aug 14, 2024
Last update
Aug 14, 2024

Study contacts

Yossi Gilgun-Sherki, PhD, MBA
study director · Executive Drug Development Consultant

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion